ImaginAb
PrivateLast Round
Series C
Extension
Sep 14, 2023
Total Funding Raised
$57.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ImaginAb is a biotechnology company that develops radiopharmaceutical imaging agents and therapies, including its proprietary CD8 ImmunoPET technology for cancer immunotherapy monitoring.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Imaging, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImaginAb Comparables
Compare ImaginAb with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CellSight Technologies | 86% | |
| Suzhou SmartNuclide Biopharmaceutical Co., Ltd. | 76% | |
| Bracco S.p.A. | 74% |
ImaginAb Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 14, 2023 | ||||
| Series C Extension | Mar 14, 2023 | ||||
| Series C | Jun 3, 2021 | ||||
| Series B Extension | Oct 9, 2017 | ||||
| Series B | May 8, 2014 | ||||
Series A | Mar 26, 2012 |
ImaginAb Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Norgine Ventures | Series C |
| Momentum Biosciences | Series A |
| Parker Institute for Cancer Immunotherapy | Series B Extension |
| Innoviva | Series C Extension |
| Cycad Group | Series A, Series B Extension, Series B, Series C |
| The Raptor Group | Series B Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 43% MoM, reaching 2.4K.
- Jun 3, 2021
$13M round led by Adage Capital Management and Cycad Group.
ImaginAb Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImaginAb's valuation, stock price, and market status.
Is ImaginAb a public or private company?
ImaginAb is a private company.
What is the current stock price of ImaginAb?
ImaginAb is a private company with no public stock price. No recent secondary market data is available.
How much is ImaginAb worth (valuation)?
Valuation information for ImaginAb is not publicly available.
Can I buy ImaginAb stock?
ImaginAb shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ImaginAb's last funding round?
ImaginAb's most recent funding round was Series C Extension on September 14, 2023.
Who are the main investors in ImaginAb?
Key investors in ImaginAb include Cycad Group, Mérieux Equity Partners.
Will ImaginAb IPO soon?
No public IPO plans have been announced for ImaginAb.
How can I track ImaginAb secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImaginAb's secondary market activity and sign up for updates.